Actinium Depreciation And Amortization vs Other Operating Expenses Analysis
ATNM Stock | USD 1.21 0.13 9.70% |
Actinium Pharmaceuticals financial indicator trend analysis is way more than just evaluating Actinium Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Actinium Pharmaceuticals is a good investment. Please check the relationship between Actinium Pharmaceuticals Depreciation And Amortization and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
Depreciation And Amortization vs Other Operating Expenses
Depreciation And Amortization vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Actinium Pharmaceuticals Depreciation And Amortization account and Other Operating Expenses. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Actinium Pharmaceuticals' Depreciation And Amortization and Other Operating Expenses is 0.81. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Actinium Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Actinium Pharmaceuticals' Depreciation And Amortization and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Actinium Pharmaceuticals are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Depreciation And Amortization i.e., Actinium Pharmaceuticals' Depreciation And Amortization and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Actinium Pharmaceuticals. It is also known as Actinium Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from Actinium Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Actinium Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.At this time, Actinium Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 4th of December 2024, Issuance Of Capital Stock is likely to grow to about 24.8 M, while Enterprise Value Over EBITDA is likely to drop (1.24).
Actinium Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Actinium Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Actinium Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 11.7M | 66.4M | 80.4M | 114.2M | 81.4M | 85.5M | |
Short Long Term Debt Total | 1.4M | 738K | 310K | 2.6M | 2.1M | 2.2M | |
Other Current Liab | 4.6M | (427K) | 691K | (498K) | (541K) | (514.0K) | |
Total Current Liabilities | 5.3M | 4.8M | 6.8M | 10.6M | 8.5M | 4.7M | |
Total Stockholder Equity | 5.6M | 61.3M | 73.5M | 66.5M | 36.4M | 18.5M | |
Net Debt | (7.8M) | (62.8M) | (77.5M) | (106.3M) | (74.6M) | (70.8M) | |
Retained Earnings | (208.8M) | (231.0M) | (255.7M) | (288.8M) | (337.6M) | (320.7M) | |
Accounts Payable | 4.6M | 4.3M | 5.5M | 10.1M | 8.0M | 8.4M | |
Cash | 9.3M | 63.6M | 77.8M | 108.9M | 76.7M | 80.5M | |
Cash And Short Term Investments | 9.3M | 63.6M | 77.8M | 108.9M | 76.7M | 80.5M | |
Common Stock Total Equity | 115.7K | 164.7K | 18K | 22K | 25.3K | 24.0K | |
Common Stock Shares Outstanding | 5.0M | 12.1M | 20.6M | 24.1M | 26.6M | 27.9M | |
Liabilities And Stockholders Equity | 11.7M | 66.4M | 80.4M | 114.2M | 81.4M | 85.5M | |
Non Current Liabilities Total | 682.3K | 311K | 3K | 37.1M | 36.6M | 38.4M | |
Other Stockholder Equity | 214.2M | 292.3M | 329.3M | 355.2M | 373.9M | 392.6M | |
Total Liab | 6.0M | 5.1M | 6.8M | 47.7M | 45.1M | 47.3M | |
Total Current Assets | 10.1M | 64.9M | 79.7M | 110.9M | 78.3M | 82.2M | |
Common Stock | 164.7K | 18K | 22K | 26K | 28K | 54.5K | |
Property Plant And Equipment Net | 1.1M | 1.0M | 639K | 2.9M | 2.9M | 3.0M | |
Current Deferred Revenue | (4.6M) | (4.3M) | 998K | 35M | 40.3M | 42.3M | |
Non Current Assets Total | 1.6M | 1.5M | 639K | 3.3M | 3.2M | 3.3M | |
Other Current Assets | 833.8K | 1.4M | 1.9M | 2.0M | 1.6M | 1.2M | |
Property Plant And Equipment Gross | 1.1M | 312K | 974K | 3.4M | 3.6M | 3.7M | |
Short Term Debt | 745.8K | 854K | 614K | 996K | 1.1M | 1.1M | |
Property Plant Equipment | 1.1M | 1.0M | 639K | 2.9M | 3.4M | 3.6M | |
Net Tangible Assets | 5.6M | 61.3M | 73.5M | 66.5M | 76.5M | 80.3M | |
Retained Earnings Total Equity | (186.9M) | (208.8M) | (231.0M) | (255.7M) | (230.2M) | (241.7M) | |
Capital Surpluse | 195.6M | 214.2M | 292.3M | 329.3M | 378.7M | 201.8M | |
Non Currrent Assets Other | 49.9K | 50K | (639K) | 302K | 313K | 328.7K | |
Other Assets | 441.0K | 441.2K | 1.2M | 302K | 1.0 | 0.95 | |
Net Invested Capital | 6.0M | 61.3M | 73.5M | 66.5M | 36.4M | 41.9M | |
Net Working Capital | 4.7M | 60.2M | 72.9M | 100.3M | 69.8M | 51.8M | |
Capital Lease Obligations | 1.0M | 738K | 310K | 2.6M | 2.1M | 1.2M | |
Capital Stock | 164.7K | 18K | 22K | 26K | 28K | 49.9K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.